Subcutaneous injection of VEGFR1 and VEGFR2 peptides (2mg, respectively) with IFA. Weekly administration, 4 times and then monthly administration, 4 times
Sponsors
Keio university school of medicine
Conditions
Neurofibromatosis type 2 with progressive schwannomaRecurrent, Progressive and Refractory Brain Tumors(hemangiopericytoma, hemangioblastoma, WHO grade II or III meningioma, chordoma, ependymoma)
Phase 1
A phase I/II study for peptide vaccine of vascular endothelial growth factor receptor-1/2 in patients with progressive schwannoma from Neurofibromatosis type 2
Active, not recruitingJPRN-UMIN000023565
Start: 2016-08-09Target: 10Updated: 2026-06-29
VEGFR1/2 Peptide Vaccine in Patients with Recurrent, Progressive and Refractory Brain Tumors
RecruitingJPRN-UMIN000029005
Start: 2017-10-01Target: 20Updated: 2026-06-29